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Abstract-The dose-ranging pharmacokinetics of phenylbutazone on periodic multiple 
oral dosing have previously been shown to be nonlinear, inasmuch as there is a pla- 
teauing of steady-state plasma concentrations with increasing dose. The mechanistic 
hypothesis of saturable protein binding, postulated to explain this behaviour bvas tested. 
in the context of whole-body pharmacokinetic modelling of the observed dose depen- 
dancy, using the circuit simulation program SPICE?. The alternate hypotheses, oper- 
ating singly or in tandem, of loss of unabsorbed drug due to gastrointestinal emptying. 
saturable absorption, change in the volume of distribution of the drug, were also ex- 
amined. Within the constraints of the proposed whole-body pharmacokinetic model. 
the absorption kinetics of increasing oral daily doses of phenylbutazone were shown 
to be saturable in their mechanism. 
INTRODUCTION 
Phenylbutazone (PBZ) is an anti-inflammatory agent introduced in 1949 for the treatment 
of rheumatoid arthritis and related disorders and for the therapy of acute gout. Burns and 
co-workers[ l] in 1953 first reported on the inability of plateau plasma levels on repeated 
divided dosing to increase linearly with increasing dose magnitudes. The three subjects 
whose data were graphed exhibited a progressive increase in plasma levels during the 
first 3 to 4 days up to a plateau concentration which was then maintained for the remainder 
time period on that dosing regimen. On increasing the daily dosage regimen a new plateau 
was reached which was not proportional to the dosage change. PBZ is highly plasma 
protein bound with a consequently long plasma tllz (range l-4 days), and Burns and co- 
workers, using equilibrium dialysis binding studies, observed that at concentrations rang- 
ing from 50-150 mg/L, PBZ was 98% protein bound but plasma protein binding decreased 
to 88% at a concentration of 250 mg/L. They therefore theorised that the nonlinear increase 
in plateau plasma level at the higher dosages was due to saturation of protein-binding sites 
at the higher dosages resulting in more free drug being available for biotransformation 
and consequently an increased amount of drug was being metabolised. Similar observa- 
tions and explanations were expressed by Orme et a/.[?]. Sioufi et a/.[31 have suggested 
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an increase in the volume of distribution as an explanation for similar observations with 
PBZ seen in their studies. A third mechanism hypothesized to explain this phenomenon 
has been that of saturable absorption most probably caused by dissolution rate limitation 
at the higher doses[4]. 
It was therefore decided to explore and hopefully discriminate between the various 
possible mechanisms by modelling PBZ pharmacokinetics on multiple dosing. The elec- 
trical circuit simulation program SPICE2 described by us in previous reports[5-71 was 
used for the modelling and simulation analysis. The mechanism theorising an increase in 
volume of distribution on increasing dose size was excluded on the basis of detailed 
mathematical analysis (explained in the Discussion) of the data of Sioufi et a1.[3]. Thus, 
only the possibilities of saturable binding at the higher doses and/or saturating PBZ ab- 
sorption on increasing doses, resulting in increased amounts of unabsorbed drug being 
eliminated in the feces by normal G.I. peristalsis, were modelled and simulated. 
METHODS 
The objective was to model and simulate the data observed by Burns and co-workers[l] 
for their subject F.M. after multiple divided oral doses of 200 mg PBZ each for 200, 400, 
800, 1600 mg daily doses. The pharmacokinetic modelling and simulation were achieved 
using the electrical circuit simulation program SPICE2 [5-71. 
The compartmental pharmacokinetic mode1 depicted in Fig. 1 was utilized. The equa- 
tion for the saturable absorption model is 
V Inan .cs 
K-n + es - KFTCP + K-d’r - KPLCP, 
where Cp and Cr are the PBZ plasma and tissue concentrations. V,,, and K, are the 
Michaelis-Menten parameters for PBZ absorption into the plasma compartment. Cs is 
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Fig. I. Pharmacokinetic model representation for simulating phenylbutazone kinetics after periodic multiple oral 
dosing in normal humans. 
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the concentration of the drug in the gastrointestinal compartment. Km, KTp and KpL are 
the rate-constants for drug transfer from plasma to tissue, tissue to plasma and plasma 
elimination constant, respectively. 
At steady-state, since K~TCP and K&ZT are very small, 
V max .C sss 
K, + csss = KPLCP~. (2) 
In the simulation circuit, the effective capacitance (volume) of compartment 1 is main- 
tained at 1 L and hence Cs = As, where As is the amount of PBZ in the gastrointestinal 
tract (daily dose). Therefore 
Knowing Cpss, As, KM and 
VrnaxlK~~,As 
Km + As 
= CPSS. (3) 
KpL for the particular subject (F.M. from Burns and co- 
workers[ I]), V max was calculated and then used in the simulation circuit. 
The SPICE2 modelling of Michaelis-Menten kinetics, multiple divided dosing, gas- 
trointestinal emptying and protein-binding dynamics has been described in detail previ- 
ously[j], and the reader is refered to the earlier report for necessary documentation. The 
following parameters were used to achieve the simulation: Plasma compartment volume 
= 3 L, tissue compartment volume = 30 L, effective gastrointestinal compartment vol- 
ume = 1 L [8]; K&KT~ = 5/3 calculated based on a distribution volume of 0.172 L/Kg 
[9] and VP = VT( 1 + KPTIKT~); PBZ tl12 for subject F.M. = 4.2 days[l]; plasma albumin 
concentration = 5 mg%[8]; Michaelis-Menten parameters for saturable absorption ki- 
netics graphically obtained to be C,,, = 185 mg/L and K, = 272 mg[4] and calculated 
V max for the simulation model = 91.5 mg using eqn (3); K equilibrium values for PBZ 
binding ranged from 1.25 x lo- I3 [ 1, 101 to 1.25 x 10” units. The gastrointestinal emptying 
cycle lasts for an hour and empties every 9 hours[8]. 
EXPERIMENTAL 
The following two sets of experiments were conducted and plasma levels obtained and 
compared after 14 days on daily dosing regimens of 200, 400, 800 and 1600 mg in divided 
doses of 200 mg each. 
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Fig. 2. SPICE2 model representation of the phenylbutazone pharmacokinetic model depicted in Fig. 1. 
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(a) Without G.I. emptying and without saturable absorption kinetics. 
(b) With G.I. emptying and without saturable kinetics, i.e. with first-order absorption 
kinetics. 
(c) With G.I. emptying and with saturable absorption kinetics. 
Set II: 
(a) Same as (a) in set I but with protein-binding circuit incorporated. 
(b) Same as (b) in Set I bur with protein-binding circuit incorporated. 
(c) Same as (c) in Set I but with protein-binding circuit incorporated. 
The SPICE2 circuit representation of the multiple divided dosing PBZ pharmacokinetic 
model shown in Fig. 1 is depicted in Fig. 2. 
RESULTS AND DISCUSSION 
The three possible mechanisms for the nonlinearity in PBZ plateau plasma level on 
increasing daily doses, namely saturable protein bindin,, 0 increased volume of distribution 
and saturable absorption due to dissolution rate limitations, were considered with the 
additional physiological limitation of as yet unabsorbed dose being periodically emptied 
into the feces. 
Detailed mathematical analyses of the data of Siouti et a1.[4], who theorized an increase 
in the volume of distribution, resulted in exclusion of this mechanism from modelling 
considerations. Briefly, using the usual methods[l I] the microconstants Kpy, KTP and 
KPL for the two-compartment pharmacokinetic model were calculated from the average 
values of the hybrid exponents and coefftcients given for the three doses. On examination 
of these microconstants it was found that the absorption rate constant, the plasma to 
tissue distribution rate constant and the elimination rate constant decreased as the dose 
increased from 100 to 600 mg. The elimination half-life increased from 45.6 to 73.7 hours, 
while the beta half-life remained virtually unchanged. Correspondingly, the calculated 
fraction of the drug in the central compartment increased from 0.61 to 0.91 and then 0.98 
for the 100 to 300 to 600 mg dose. Further, as the dose increased from 100 to 600 mg the 
tin elimination and tllz beta began to coalesce and become indistinguishable. All of this 
suggests that as the dose was increased, whatever fraction of the dose that was absorbed 
was concentrated in the plasma or central compartment and not distributed increasingly 
into the tissues. Again using the usual equations[ 1 I], and assuming the volume of distri- 
bution of the central compartment o be 3 L (plasma volume), F, the fraction of the dose 
absorbed was calculated for all three doses and was found to decrease from 0.56 for the 
100 mg dose to 0.35 for the 300 mg and 0.29 for the 600 mg single dose. Using regression 
techniques the minimum fraction absorbed (solubility dependent) was obtained as 0.28. 
Using similar mathematical analysis of the multiple dose data for subject FM. of Bums 
and co-workers[l], the minimum fraction absorbed at steady-state, using the same pa- 
rameters used in the simulations described in this paper, was calculated (with an equally 
good correlation coefficient, >0.97) to be 0.26, which, fortuitously, is very consistent to 
that obtained after single dosing. For the same data, moreover, the accumulation in the 
body was calculated to be 0.4, 0.26, 0.18 and 0.10 for the 200, 400, 800 and 1600 mg daily 
doses, respectively. 
The results of the simulations attempting to discriminate between the protein binding 
and saturable absorption mechanisms are tabulated in Table 1. 
The results show that incorporating the mass action law governed protein binding into 
the model does not affect the PBZ plasma concentrations (over an extremely wide range 
of equilibrium binding constants) while the gastrointestinal emptying cycle does. Phen- 
ylbutazone is known to be a very poorly extracted drug and hence its liver metabolism 
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Table I. Phenylbutazone plasma level (mg/L) obtained on SPICE2 modelling and simulation of periodic 
multiple oral dosing at different daily dose. K ,, = rate constant for drug absorption (time-‘). The equilibrium 
binding rate constant K,, = KflKb. The magnitudes of Kr/Kb were varied such that the ratio KfIKb was 
always equal in value to the literature value I .25 x lO-‘3 [ 1, IO] which is the value used in the simulation 
results reported in this table. For further details see Methods and Ref. [j]. 
is rather insensitive to changes in free fraction that may occur with binding changes at 
high plasma concentrations (>150 mg/L). This lack of observed effect of protein binding 
on PBZ clearance has also been corroborated recently in a multiple-dose ranging British 
study wherein the binding saturation and consequent increased metabolism hypothesis 
were particularly evaluated[l2]. The simulation results also show fecal percentage ac- 
cumulations of 0.6, 1.7, 3.3 and 9.95 for the 200,400, 800, 1600 mg daily doses. The results 
of the simulations with the saturable absorption mechanism operating give simulated PBZ 
plateau plasma concentration values which are highly correlated to those observed by 
Burns and co-workers[l] for their subject F.M. (Fig. 3, r = 0.984). The correlation coef- 
ficient between observed and calculated (for the saturable absorption mechanistic model) 
using graphically obtained C,,, and K, values for subject F.M. was 0.989 as noted pre- 
viously[4]. Further, if the same parameter used in the simulation are used and fraction 
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Fig. 3. Comparison of observed plateau phenylbutazone levels with simulated plateau levels, obtained using 
SPICEZ, for subject F.M. of Bums and co-workers[l]. 
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absorbed is assumed to be 1, the calculated steady-state plasma PBZ levels at the 200, 
400, 800, 1600 mg daily doses for subject F.M. are 100.7, 201.3, 402.7 and 805.7 versus 
the observed levels of 80, 103, 145 and 159. All of this implicates the saturable absorption 
model as being best suited to describe the observed data for PBZ plateau plasma levels 
on periodic multiple dosing. 
The question then remains as to why was this mechanism the only loose end not cor- 
rectly tied up in the otherwise superb and state-of-the-art (even by present standards!) 
clinical pharmacological work on PBZ by Burns and co-workers? The explanation is found 
on close examination of their data. They reported less than 5% of PBZ in the feces collected 
for a 72 hour period, after the 800 mg daily dose, which roughly corresponds to the 
attainment of the plateau plasma level. However, increasing amounts of PBZ in the feces 
would be expected to appear only after the plateau level is reached, i.e. after 72 hours. 
Secondly, if one examines their figure depicting the plateau levels for the three subjects 
on each daily dose regimen, it can be seen that at the 1600 mg daily dose level, except 
for F.M. (reaching a level of 150 mg/L), neither of the other two subjects exceed 150 mgl 
L. This is the concentration beyond which nonlinear binding with increased percent free 
was found by Burns and co-workers[l] in their equilibrium dialysis binding experiments. 
Moreover, in the light of recent work with PBZ by others, showing that its dissolution 
ionization kinetics are noninstantaneous[l3] in accord with its very low solubility, the 
dissolution rate limited model makes perfect sense. 
CONCLUSIONS 
The detailed modelling and simulation of PBZ pharmacokinetics after periodic repeated 
daily dosing using the simulation program SPICE2 conclusively demonstrates the validity 
of the dissolution rate limited saturable absorption model for predicting steady-state PBZ 
levels. The saturable absorption model predicts PBZ steady-state levels in close agreement 
with those observed previously in the one subject, in contrast to the saturable-binding- 
increased biotransformation model. 
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